Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome

S. Tsuji, H. Matsuzaki, M. Iseki, A. Nagasu, H. Hirano, K. Ishihara, N. Ueda, Y. Honda, T. Horiuchi, R. Nishikomori, Y. Morita, T. Mukai

Research output: Contribution to journalArticle

Abstract

Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autoinflammatory disease that is caused by heterozygous mutations in the TNFRSF1A gene. Although more than 150 TNFRSF1A mutations have been reported to be associated with TRAPS phenotypes only a few, such as p.Thr79Met (T79M) and cysteine mutations, have been functionally analyzed. We identified two TRAPS patients in one family harboring a novel p.Gly87Val (G87V) mutation in addition to a p.Thr90Ile (T90I) mutation in TNFRSF1A. In this study, we examined the functional features of this novel G87V mutation. In-vitro analyses using mutant TNF receptor 1 (TNF-R1)-over-expressing cells demonstrated that this mutation alters the expression and function of TNF-R1 similar to that with the previously identified pathogenic T79M mutation. Specifically, cell surface expression of the mutant TNF-R1 in transfected cells was inhibited with both G87V and T79M mutations, whereas the T90I mutation did not affect this. Moreover, peripheral blood mononuclear cells (PBMCs) from TRAPS patients harboring the G87V and T90I mutations showed increased mitochondrial reactive oxygen species (ROS). Furthermore, the effect of various Toll-like receptor (TLR) ligands on inflammatory responses was explored, revealing that PBMCs from TRAPS patients are hyper-responsive to TLR-2 and TLR-4 ligands and that interleukin (IL)-8 and granulocyte–macrophage colony-stimulating factor (GM-CSF) are likely to be involved in the pathogenesis of TRAPS. These findings suggest that the newly identified G87V mutation is one of the causative mutations of TRAPS. Our findings based on unique TRAPS-associated mutations provide novel insight for clearer understanding of inflammatory responses, which would be basic findings of developing a new therapeutic and prophylactic approach to TRAPS.

Original languageEnglish
Pages (from-to)416-429
Number of pages14
JournalClinical and Experimental Immunology
Volume198
Issue number3
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

Mutation
Autosomal Dominant Familial Periodic Fever
Blood Cells
Tumor Necrosis Factor-alpha
Ligands
Toll-Like Receptor 2
Toll-Like Receptor 4
Tumor Necrosis Factor Receptors
Toll-Like Receptors
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-8
Cysteine
Reactive Oxygen Species
Phenotype
Genes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome. / Tsuji, S.; Matsuzaki, H.; Iseki, M.; Nagasu, A.; Hirano, H.; Ishihara, K.; Ueda, N.; Honda, Y.; Horiuchi, T.; Nishikomori, R.; Morita, Y.; Mukai, T.

In: Clinical and Experimental Immunology, Vol. 198, No. 3, 01.12.2019, p. 416-429.

Research output: Contribution to journalArticle

Tsuji, S, Matsuzaki, H, Iseki, M, Nagasu, A, Hirano, H, Ishihara, K, Ueda, N, Honda, Y, Horiuchi, T, Nishikomori, R, Morita, Y & Mukai, T 2019, 'Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome', Clinical and Experimental Immunology, vol. 198, no. 3, pp. 416-429. https://doi.org/10.1111/cei.13365
Tsuji, S. ; Matsuzaki, H. ; Iseki, M. ; Nagasu, A. ; Hirano, H. ; Ishihara, K. ; Ueda, N. ; Honda, Y. ; Horiuchi, T. ; Nishikomori, R. ; Morita, Y. ; Mukai, T. / Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome. In: Clinical and Experimental Immunology. 2019 ; Vol. 198, No. 3. pp. 416-429.
@article{e1ace29a12fd48d4934b30a6ce3e4d5a,
title = "Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome",
abstract = "Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autoinflammatory disease that is caused by heterozygous mutations in the TNFRSF1A gene. Although more than 150 TNFRSF1A mutations have been reported to be associated with TRAPS phenotypes only a few, such as p.Thr79Met (T79M) and cysteine mutations, have been functionally analyzed. We identified two TRAPS patients in one family harboring a novel p.Gly87Val (G87V) mutation in addition to a p.Thr90Ile (T90I) mutation in TNFRSF1A. In this study, we examined the functional features of this novel G87V mutation. In-vitro analyses using mutant TNF receptor 1 (TNF-R1)-over-expressing cells demonstrated that this mutation alters the expression and function of TNF-R1 similar to that with the previously identified pathogenic T79M mutation. Specifically, cell surface expression of the mutant TNF-R1 in transfected cells was inhibited with both G87V and T79M mutations, whereas the T90I mutation did not affect this. Moreover, peripheral blood mononuclear cells (PBMCs) from TRAPS patients harboring the G87V and T90I mutations showed increased mitochondrial reactive oxygen species (ROS). Furthermore, the effect of various Toll-like receptor (TLR) ligands on inflammatory responses was explored, revealing that PBMCs from TRAPS patients are hyper-responsive to TLR-2 and TLR-4 ligands and that interleukin (IL)-8 and granulocyte–macrophage colony-stimulating factor (GM-CSF) are likely to be involved in the pathogenesis of TRAPS. These findings suggest that the newly identified G87V mutation is one of the causative mutations of TRAPS. Our findings based on unique TRAPS-associated mutations provide novel insight for clearer understanding of inflammatory responses, which would be basic findings of developing a new therapeutic and prophylactic approach to TRAPS.",
author = "S. Tsuji and H. Matsuzaki and M. Iseki and A. Nagasu and H. Hirano and K. Ishihara and N. Ueda and Y. Honda and T. Horiuchi and R. Nishikomori and Y. Morita and T. Mukai",
year = "2019",
month = "12",
day = "1",
doi = "10.1111/cei.13365",
language = "English",
volume = "198",
pages = "416--429",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome

AU - Tsuji, S.

AU - Matsuzaki, H.

AU - Iseki, M.

AU - Nagasu, A.

AU - Hirano, H.

AU - Ishihara, K.

AU - Ueda, N.

AU - Honda, Y.

AU - Horiuchi, T.

AU - Nishikomori, R.

AU - Morita, Y.

AU - Mukai, T.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autoinflammatory disease that is caused by heterozygous mutations in the TNFRSF1A gene. Although more than 150 TNFRSF1A mutations have been reported to be associated with TRAPS phenotypes only a few, such as p.Thr79Met (T79M) and cysteine mutations, have been functionally analyzed. We identified two TRAPS patients in one family harboring a novel p.Gly87Val (G87V) mutation in addition to a p.Thr90Ile (T90I) mutation in TNFRSF1A. In this study, we examined the functional features of this novel G87V mutation. In-vitro analyses using mutant TNF receptor 1 (TNF-R1)-over-expressing cells demonstrated that this mutation alters the expression and function of TNF-R1 similar to that with the previously identified pathogenic T79M mutation. Specifically, cell surface expression of the mutant TNF-R1 in transfected cells was inhibited with both G87V and T79M mutations, whereas the T90I mutation did not affect this. Moreover, peripheral blood mononuclear cells (PBMCs) from TRAPS patients harboring the G87V and T90I mutations showed increased mitochondrial reactive oxygen species (ROS). Furthermore, the effect of various Toll-like receptor (TLR) ligands on inflammatory responses was explored, revealing that PBMCs from TRAPS patients are hyper-responsive to TLR-2 and TLR-4 ligands and that interleukin (IL)-8 and granulocyte–macrophage colony-stimulating factor (GM-CSF) are likely to be involved in the pathogenesis of TRAPS. These findings suggest that the newly identified G87V mutation is one of the causative mutations of TRAPS. Our findings based on unique TRAPS-associated mutations provide novel insight for clearer understanding of inflammatory responses, which would be basic findings of developing a new therapeutic and prophylactic approach to TRAPS.

AB - Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autoinflammatory disease that is caused by heterozygous mutations in the TNFRSF1A gene. Although more than 150 TNFRSF1A mutations have been reported to be associated with TRAPS phenotypes only a few, such as p.Thr79Met (T79M) and cysteine mutations, have been functionally analyzed. We identified two TRAPS patients in one family harboring a novel p.Gly87Val (G87V) mutation in addition to a p.Thr90Ile (T90I) mutation in TNFRSF1A. In this study, we examined the functional features of this novel G87V mutation. In-vitro analyses using mutant TNF receptor 1 (TNF-R1)-over-expressing cells demonstrated that this mutation alters the expression and function of TNF-R1 similar to that with the previously identified pathogenic T79M mutation. Specifically, cell surface expression of the mutant TNF-R1 in transfected cells was inhibited with both G87V and T79M mutations, whereas the T90I mutation did not affect this. Moreover, peripheral blood mononuclear cells (PBMCs) from TRAPS patients harboring the G87V and T90I mutations showed increased mitochondrial reactive oxygen species (ROS). Furthermore, the effect of various Toll-like receptor (TLR) ligands on inflammatory responses was explored, revealing that PBMCs from TRAPS patients are hyper-responsive to TLR-2 and TLR-4 ligands and that interleukin (IL)-8 and granulocyte–macrophage colony-stimulating factor (GM-CSF) are likely to be involved in the pathogenesis of TRAPS. These findings suggest that the newly identified G87V mutation is one of the causative mutations of TRAPS. Our findings based on unique TRAPS-associated mutations provide novel insight for clearer understanding of inflammatory responses, which would be basic findings of developing a new therapeutic and prophylactic approach to TRAPS.

UR - http://www.scopus.com/inward/record.url?scp=85071777077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071777077&partnerID=8YFLogxK

U2 - 10.1111/cei.13365

DO - 10.1111/cei.13365

M3 - Article

C2 - 31429073

AN - SCOPUS:85071777077

VL - 198

SP - 416

EP - 429

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -